The DNA methyl transferase inhibitor, 5′-aza-2-deoxycitidine, enhances the apoptotic effect of Mevastatin in human leukemia HL-60 cells

Human and Experimental Toxicology

Volumn 33, Issue 4, 2014, Pages 414-423

  Yilmaz, A ^a   Menevse, S ^a   Konac, E ^a   Alp, E ^b  

^a GAZI UNIVERSITY   (Turkey)

^b GIRESUN UNIVERSITY   (Turkey)

Author keywords

5 aza 2 deoxycitidine; apoptosis; DNA methylation; gene expression; HL 60 cell line; Mevastatin; real time PCR

Indexed keywords

5' AZA 2 DEOXYCITIDINE; CASPASE 3; CASPASE 8; CASPASE 9; COMPACTIN; DNA METHYLTRANSFERASE INHIBITOR; MESSENGER RNA; PROTEIN BAX; PROTEIN BCL 2; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS;

APOPTOSIS; ARTICLE; CELL DEATH; CELL STRAIN HL 60; DNA FRAGMENTATION; DNA SYNTHESIS; DRUG POTENTIATION; ENZYME ACTIVATION; GENE EXPRESSION; HUMAN; HUMAN CELL; LEUKEMIA CELL; METHYLATION; PRIORITY JOURNAL;

5′-AZA-2-DEOXYCITIDINE; APOPTOSIS; DNA METHYLATION; GENE EXPRESSION; HL-60 CELL LINE; MEVASTATIN; REAL-TIME PCR;

APOPTOSIS; AZACITIDINE; CASPASES; DNA MODIFICATION METHYLASES; DNA REPLICATION; DRUG SYNERGISM; ENZYME ACTIVATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; HL-60 CELLS; HUMANS; L-LACTATE DEHYDROGENASE; LEUKEMIA; LOVASTATIN; METHYLATION; MICROSCOPY, FLUORESCENCE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 84897905039     PISSN: 09603271     EISSN: 14770903     Source Type: Journal    
DOI: 10.1177/0960327113499050     Document Type: Article

References (35)

1. Sassano A, Platanias LC. Statins in tumor suppression. Canc Lett. 2008 ; 260 ((1-2)). 11-19
2. Chan KK, Oza AM, Siu LL. The statins as anticancer agents. Clin Canc Res. 2003 ; 9 (1). 10-19
3. Wang CY, Liu PY, Liao JK. Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. Trends Mol Med. 2008 ; 14 (1). 37-44
4. Jakobisiak M, Golab J. Statins can modulate effectiveness of antitumor therapeutic modalities. Med Res Rev. 2010 ; 30 (1). 102-135
5. Osmak M. Statins and cancer: current and future prospects. Canc Lett. 2012 ; 324 (1). 1-12
6. Florean C, Schnekenburger M, Grandjenette C, et al. Epigenomics of leukemia: from mechanisms to therapeutic applications. Epigenomics. 2011 ; 3 (5). 581-609
7. Gopisetty G, Ramachandran K, Singal R. DNA methylation and apoptosis. Mol Immunol. 2006 ; 43 (11). 1729-1740
8. Lübbert M. DNA methylation inhibitors in the treatment of leukemias, myelodysplastic syndromes and hemoglobinopathies: clinical results and possible mechanisms of action. Curr Top Microbiol Immunol. 2000 ; 249: 135-164
9. Fang X, Zheng C, Liu Z, Ekman P, et al. Enhanced sensitivity of prostate cancer DU145 cells to cisplatinum by 5-aza-2′-deoxycytidine. Oncol Rep. 2004 ; 12 (3). 523-526
10. Senkoylu A, Yilmaz A, Ergun MA, et al. Effect of strontium ranelate on hydrogen peroxide-induced apoptosis of CRL-11372 cells. Biochem Genet. 2008 ; 46 ((3-4)). 197-205
11. Martinez R, Setien F, Voelter C, et al. CpG island promoter hypermethylation of the pro-apoptotic gene caspase-8 is a common hallmark of relapsed glioblastoma multiforme. Carcinogenesis. 2007 ; 28 (6). 1264-1268
12. Gonzalez-Gomez P, Bello MJ, Lomas J, et al. Aberrant methylation of multiple genes in neuroblastic tumours. relationship with MYCN amplification and allelic status at 1p. Eur J Canc. 2003 ; 39 (10). 1478-1485
13. Pfaffl MW, Horgan GW, Dempfle L. Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res. 2002 ; 30 (9). e36
14. Buhaescu I, Izzedine H. Mevalonate pathway: a review of clinical and therapeutical implications. Clin Biochem. 2007 ; 40 ((9-10)). 575-584
15. Ho YK, Smith RG, Brown MS, et al. Low-density lipoprotein (LDL) receptor activity in human acute myelogenous leukemia cells. Blood. 1978 ; 52 (6). 1099-1114
16. Vitols S, Gahrton G, Ost A, et al. Elevated low density lipoprotein receptor activity in leukemic cells with monocytic differentiation. Blood. 1984 ; 63 (5). 1186-1193
17. Peeters SD, van der Kolk DM, de Haan G, et al. Selective expression of cholesterol metabolism genes in normal CD34+ CD38- cells with a heterogeneous expression pattern in AML cells. Exp Hematol. 2006 ; 34 (5). 622-630
18. Li HY, Appelbaum FR, Willman CL, et al. Cholesterol-modulating agents kill acute myeloid leukemia cells and sensitize them to therapeutics by blocking adaptive cholesterol responses. Blood. 2003 ; 101 (9). 3628-3634
19. Banker DE, Mayer SJ, Li HY, et al. Cholesterol synthesis and import contribute to protective cholesterol increments in acute myeloid leukemia cells. Blood. 2004 ; 104 (6). 1816-1824
20. Stirewalt DL, Appelbaum FR, Willman CL, et al. Mevastatin can increase toxicity in primary AMLs exposed to standard therapeutic agents, but statin efficacy is not simply associated with ras hotspot mutations or overexpression. Leuk Res. 2003 ; 27 (2). 133-145
21. Nishida S, Matsuoka H, Tsubaki M, et al. Mevastatin induces apoptosis in HL60 cells dependently on decrease in phosphorylated ERK. Mol Cell Biochem. 2005 ; 269 ((1-2)). 109-114
22. Gomyo Y, Sasaki J, Branch C, et al. 5-aza-2′-deoxycytidine upregulates caspase-9 expression cooperating with p53-induced apoptosis in human lung cancer cells. Oncogene. 2004 ; 23 (40). 6779-6787
23. Shang D, Liu Y, Matsui Y, et al. Demethylating agent 5-aza-2′- deoxycytidine enhances susceptibility of bladder transitional cell carcinoma to Cisplatin. Urology. 2008 ; 71 (6). 1220-1225
24. Wong WW, Dimitroulakos J, Minden MD, et al. HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis. Leukemia. 2002 ; 16 (4). 508-519
25. Kawata S, Yamasaki E, Nagase T, et al. Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial. Br J Canc. 2001 ; 84 (7). 886-891
26. Wang IK, Lin-Shiau SY, Lin JK. Induction of apoptosis by lovastatin through activation of caspase-3 and DNase II in leukaemia HL-60 cells. Pharmacol Toxicol. 2000 ; 86 (2). 83-91
27. Marcelli M, Cunningham GR, Haidacher SJ, et al. Caspase-7 is activated during lovastatin-induced apoptosis of the prostate cancer cell line LNCaP. Canc Res. 1998 ; 58 (1). 76-83
28. Buchholz TA, Davis DW, McConkey DJ, et al. Chemotherapy-induced apoptosis and Bcl-2 levels correlate with breast cancer response to chemotherapy. Canc J. 2003 ; 9 (1). 33-41
29. Minko T, Batrakova EV, Li S, et al. Pluronic block copolymers alter apoptotic signal transduction of doxorubicin in drug-resistant cancer cells. J Control Release. 2005 ; 105 (3). 269-278
30. Miao ZH, Tang T, Zhang YX. Cytotoxicity, apoptosis induction and downregulation of MDR-1 expression by the anti-topoisomerase II agent, salvicine, in multidrug-resistant tumor cells. Int J Canc. 2003 ; 106 (1). 108-115
31. Holcik M. Translational upregulation of the X-linked inhibitor of apoptosis. Ann N Y Acad Sci. 2003 ; 1010: 249-258
32. Tamm I, Kornblau SM, Segall H, et al. Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias. Clin Canc Res. 2000 ; 6 (5). 1796-1803
33. Agarwal B, Bhendwal S, Halmos B, et al. Lovastatin augments apoptosis induced by chemotherapeutic agents in colon cancer cells. Clin Canc Res. 1999 ; 5 (8). 2223-2229
34. Dimitroulakos J, Thai S, Wasfy GH, et al. Lovastatin induces a pronounced differentiation response in acute myeloid leukemias. Leuk Lymphoma. 2000 ; 40 ((1-2)). 167-178
35. Nguyen CT, Weisenberger DJ, Velicescu M, et al. Histone H3-lysine 9 methylation is associated with aberrant gene silencing in cancer cells and is rapidly reversed by 5-aza-2′-deoxycytidine. Canc Res. 2002 ; 62 (22). 6456-6461